These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 27976373)

  • 21. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480.
    Xin H; Herrmann A; Reckamp K; Zhang W; Pal S; Hedvat M; Zhang C; Liang W; Scuto A; Weng S; Morosini D; Cao ZA; Zinda M; Figlin R; Huszar D; Jove R; Yu H
    Cancer Res; 2011 Nov; 71(21):6601-10. PubMed ID: 21920898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heme oxygenase-1 inhibition mediates Gas6 to enhance bortezomib-sensitivity in multiple myeloma via ERK/STAT3 axis.
    Zhang Z; Wang W; Ma D; Xiong J; Kuang X; Zhang S; Fang Q; Wang J
    Aging (Albany NY); 2020 Apr; 12(8):6611-6629. PubMed ID: 32298237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.
    Zhang C; Xu X; Trotter TN; Gowda PS; Lu Y; Suto MJ; Javed A; Murphy-Ullrich JE; Li J; Yang Y
    Mol Cancer Ther; 2022 Feb; 21(2):347-358. PubMed ID: 34907087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
    Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
    Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An inhibitor of cholesterol absorption displays anti-myeloma activity by targeting the JAK2-STAT3 signaling pathway.
    Xu X; Han K; Zhu J; Mao H; Lin X; Zhang Z; Cao B; Zeng Y; Mao X
    Oncotarget; 2016 Nov; 7(46):75539-75550. PubMed ID: 27705908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib.
    Camiolo G; Barbato A; Giallongo C; Vicario N; Romano A; Parrinello NL; Parenti R; Sandoval JC; García-Moreno D; Lazzarino G; Avola R; Palumbo GA; Mulero V; Li Volti G; Tibullo D; Di Raimondo F
    Redox Biol; 2020 Sep; 36():101611. PubMed ID: 32863212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Collaboration of cancer-associated fibroblasts and tumour-associated macrophages for neuroblastoma development.
    Hashimoto O; Yoshida M; Koma Y; Yanai T; Hasegawa D; Kosaka Y; Nishimura N; Yokozaki H
    J Pathol; 2016 Oct; 240(2):211-23. PubMed ID: 27425378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
    De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
    Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using macrophage activation to augment immunotherapy of established tumours.
    Fridlender ZG; Jassar A; Mishalian I; Wang LC; Kapoor V; Cheng G; Sun J; Singhal S; Levy L; Albelda SM
    Br J Cancer; 2013 Apr; 108(6):1288-97. PubMed ID: 23481183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma.
    Xu R; Li Y; Yan H; Zhang E; Huang X; Chen Q; Chen J; Qu J; Liu Y; He J; Yi Q; Cai Z
    Cell Death Dis; 2019 Oct; 10(10):781. PubMed ID: 31611552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
    Mougiakakos D; Bach C; Böttcher M; Beier F; Röhner L; Stoll A; Rehli M; Gebhard C; Lischer C; Eberhardt M; Vera J; Büttner-Herold M; Bitterer K; Balzer H; Leffler M; Jitschin S; Hundemer M; Awwad MHS; Busch M; Stenger S; Völkl S; Schütz C; Krönke J; Mackensen A; Bruns H
    Cancer Immunol Res; 2021 Mar; 9(3):265-278. PubMed ID: 33563611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
    Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Onionin A inhibits ovarian cancer progression by suppressing cancer cell proliferation and the protumour function of macrophages.
    Tsuboki J; Fujiwara Y; Horlad H; Shiraishi D; Nohara T; Tayama S; Motohara T; Saito Y; Ikeda T; Takaishi K; Tashiro H; Yonemoto Y; Katabuchi H; Takeya M; Komohara Y
    Sci Rep; 2016 Jul; 6():29588. PubMed ID: 27404320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor and Antimetastatic Activity of Synthetic Hydroxystilbenes Through Inhibition of Lymphangiogenesis and M2 Macrophage Differentiation of Tumor-associated Macrophages.
    Kimura Y; Sumiyoshi M; Baba K
    Anticancer Res; 2016 Jan; 36(1):137-48. PubMed ID: 26722037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypoxia promotes glioma-associated macrophage infiltration via periostin and subsequent M2 polarization by upregulating TGF-beta and M-CSFR.
    Guo X; Xue H; Shao Q; Wang J; Guo X; Chen X; Zhang J; Xu S; Li T; Zhang P; Gao X; Qiu W; Liu Q; Li G
    Oncotarget; 2016 Dec; 7(49):80521-80542. PubMed ID: 27602954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythropoietin alleviates hyperglycaemia-associated inflammation by regulating macrophage polarization via the JAK2/STAT3 signalling pathway.
    Cui J; Zhang F; Cao W; Wang Y; Liu J; Liu X; Chen T; Li L; Tian J; Yu B
    Mol Immunol; 2018 Sep; 101():221-228. PubMed ID: 30007232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alantolactone induces G1 phase arrest and apoptosis of multiple myeloma cells and overcomes bortezomib resistance.
    Yao Y; Xia D; Bian Y; Sun Y; Zhu F; Pan B; Niu M; Zhao K; Wu Q; Qiao J; Fu C; Li Z; Xu K
    Apoptosis; 2015 Aug; 20(8):1122-33. PubMed ID: 26033479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
    Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
    Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway.
    Zhang B; Li B; Xie Y; Chang S; Xu Z; Hu H; Chen G; Zhang T; He J; Wu X; Zhu H; Lai W; Song D; Lu Y; Jia X; Zhu W; Shi J
    Acta Biochim Biophys Sin (Shanghai); 2023 Feb; 55(2):215-224. PubMed ID: 36815376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.